Preparation, quality control and biodistribution studies of two [ 111In]-rituximab immunoconjugates

Scientia Pharmaceutica

Volumn 76, Issue 2, 2008, Pages 151-170

  Jalilian, Amir R ^a   Sardari, Darush ^b   Kia, Leila ^b   Rowshanfarzad, Pejman ^a   Garousi, Javad ^a   Akhlaghi, Mehdi ^a   Shanehsazzadeh, Saeed ^a   Mirzaii, Mohammad ^a  

^a AGRICULTURAL MEDICAL AND INDUSTRIAL RESEARCH SCHOOL   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Biodistribution; Indium 111; Radiolabeling; Rituximab; Targetted therapy

Indexed keywords

ANTIBODY CONJUGATE; CD20 ANTIGEN; CHELATING AGENT; INDIUM 111; N SUCCINIMIDYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; N SUCCINIMIDYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RITUXIMAB IN 111; PENTETIC ACID; PENTETIC ACID RITUXIMAB IN 111; RADIOPHARMACEUTICAL AGENT; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; LYMPHOMA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; QUALITY CONTROL; RADIOLYSIS; RAT;

EID: 46249083605     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0804-07     Document Type: Article

References (26)

1. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol.1999; 17: 3793-3803.
2. Eary JF, Press OW, Badger CC, Durack LD, Richter DK, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL. Imaging and treatment of B-cell lymphoma. J Nucl Med. 1990; 31: 1257-1268.
3. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W, Finston R, Day-Lollini R, Goris ML. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res. 1990; 50: 4935-4940.
4. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999; 93: 1062-1066.
5. Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomäcker K, Fischer T, Eschner T, Pogge von Strandmann E, Schicha H, Engert A, Schnell R. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol. 2005; 74: 348-352. [doi:10.1111/j.1600-0609.2004.00401.x]
6. Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP, Brechbiel MW. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N′,N‴- tetraacetic acid for radiolabeling proteins. Nucl Med Biol. 2003; 30: 581-595. [doi:10.1016/S0969-8051(03)00033-7]
7. Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, Kinscherf ERM, Haberkorna U. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol. 2005; 32: 287-292. [doi:10.1016/j.nucmedbio.2005.01.002]
8. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, Maecke HR, Larson SM. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002; 29: 147-157. [doi:10.1016/S0969-8051(01)00290-6]
9. McDevitt MR, Ma D, Simon J, Frank K, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot. 2002; 57: 841-847. [doi:10.1016/S0969-8043(02)00167-7]
10. Smith CJ, Galib H, Sieckmanc GL, Hayes DL, Owen NK, Mazuru DJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003; 30: 101-109. [doi:10.1016/S0969-8051(02)00391-8]
11. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000; 27: 93-100. [doi:10.1016/S0969-8051(99)00086-4]
12. Gmeiner Stopar T, Mlinaric-Rascan I, Fettich J, Hojker S, Mather SJ. (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent. Eur J Nucl Med Mol Imaging 2006; 33: 53-59. [doi:10.1007/s00259-005-1838-4]
13. Lang L, Eckelman WC. One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot. 1994; 45: 1155-1163. [doi:10.1016/0969-8043(94)90031-0]
14. Smith-Jones P, Solit DB, Akhurst T, Afroze F, Rosen M, Larsen SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nature Biotechnology. 2004; 22: 701-706. [doi:10.1038/nbt968]
15. http://www.pathologyoutlines.com/lymphoma.html
16. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program. 2001; 221-240.
17. Rituxan® (Roche) pamphlet, P.1, chapter B. CCO Formulary, Revised 2004/2005.
18. Sadeghpour H, Jalilian AR, Akhlaghi M, Kamali-dehghan M, Mirzaii M. Preparation and Biodistribution of [111In]-rHuEpo for Erythropoietin Receptor Imaging. J Radioanal Nucl Chem. 2008; 278: 117-122. [doi:10.1007/s1096700772121]
19. Marczenko Z. In: Spectrophotometric determination of elements. New York: John Wiley & Sons, 1976: 238-240.
20. Marczenko Z. In: Spectrophotometric determination of elements. New York: John Wiley & Sons, 1976: 176-179.
21. Hnatowich DJ, Layne WW, Child RL, Lanteigne D, Davis MA, Griffin TW, Doherty PW. Radioactive labeling of antibody: a simple and efficient method. Science. 1983; 220: 613-619. [doi:10.1126/science.6836304]
22. Banerjee S, Das T, Chakraborty S, Samuel G, Korde A, Srivastava S, Venkatesha M, Pillai MRA. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl Med Biol. 2004; 31: 753-759. [doi:10.1016/j. nucmedbio.2004.04.002]
23. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M. Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. Bioconjug Chem. 2005; 16: 237-240. [doi:10.1021/bc034216c]
24. Pandey U, Mukherjee A, Sarma HD, Das T, Pillai MRA, Venkatesha M. Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intravascular radionuclide therapy. Applied Radiat Isotopes. 2002; 57: 313-318. [doi:10.1016/S0969-8043(02)00103-3]
25. Green MA, Welch MJ. Gallium radiopharmaceutical chemistry. Int J Rad Appl Instrum B. 1989; 16: 435-448.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680-685. [doi:10.1038/227680a0]